106 related articles for article (PubMed ID: 17581304)
1. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Petrioli R; Paolelli L; Francini E; Marsili S; Pascucci A; Sciandivasci A; de Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
Anticancer Drugs; 2007 Aug; 18(7):817-20. PubMed ID: 17581304
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
Pagliaro LC; Perez CA; Tu SM; Daliani DD
Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
[TBL] [Abstract][Full Text] [Related]
4. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Tsimafeyeu I; Demidov L; Kharkevich G; Petenko N; Galchenko V; Sinelnikov I; Naidzionak U
Am J Clin Oncol; 2012 Jun; 35(3):251-4. PubMed ID: 21358295
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
[TBL] [Abstract][Full Text] [Related]
6. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
7. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
9. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
10. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
Jhaveri KD; Flombaum C; Shah M; Latcha S
J Oncol Pharm Pract; 2012 Mar; 18(1):140-7. PubMed ID: 22392964
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer.
Lorvidhaya V; Chitapanarux I; Phromratanapongse P; Kamnerdsupaphon P; Tharavichitkul E; Lertsanguansinchai P; Hsieh CY; Sukthomya V
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1271-5. PubMed ID: 20647708
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Chua D; Wei WI; Sham JS; Au GK
Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
[TBL] [Abstract][Full Text] [Related]
13. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
14. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Stadler WM; Desai AA; Quinn DI; Bukowski R; Poiesz B; Kardinal CG; Lewis N; Makalinao A; Murray P; Torti FM
Cancer Chemother Pharmacol; 2008 Apr; 61(4):689-94. PubMed ID: 17569043
[TBL] [Abstract][Full Text] [Related]
15. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Kotsori AA; Noble JL; Ashley S; Johnston S; Smith IE
Breast; 2010 Oct; 19(5):377-81. PubMed ID: 20392643
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.
Feliu J; Escudero P; Llosa F; Bolaños M; Vicent JM; Yubero A; Sanz-Lacalle JJ; Lopez R; Lopez-Gómez L; Casado E; Gómez-Reina MJ; González-Baron M
J Clin Oncol; 2005 May; 23(13):3104-11. PubMed ID: 15860870
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
Bajetta E; Procopio G; Celio L; Gattinoni L; Della Torre S; Mariani L; Catena L; Ricotta R; Longarini R; Zilembo N; Buzzoni R
J Clin Oncol; 2005 Apr; 23(10):2155-61. PubMed ID: 15710946
[TBL] [Abstract][Full Text] [Related]
18. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Petrioli R; Pascucci A; Francini E; Marsili S; Fiaschi AI; Civitelli S; Tanzini G; Battistelli S; Lorenzi M; Roviello F; Francini G;
Anticancer Drugs; 2008 Jan; 19(1):91-6. PubMed ID: 18043134
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
